Gilead Sciences' SWOT analysis: stock outlook shaped by HIV and oncology progress
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Business Wire1d
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV
CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...
Galapagos To Spin Off Innovative Medicines Business
Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...
PMLiVE9d
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to ...
Precision Diagnostics & Medicine Market worth $246.66 billion by 2029 with 11.1% CAGR | MarketsandMarkets™
The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of ...